Neurovia Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Neurovia General Information

Description

Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy, enabling X-ALD patients to get treatment for their rare genetic disease.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 1700 Owens Street
  • Suite 525
  • San Francisco, CA 94158
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 1700 Owens Street
  • Suite 525
  • San Francisco, CA 94158
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurovia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Nov-2018 Completed Out of Business
1. Early Stage VC (Series A) 25-May-2017 Completed Clinical Trials - Phase 1
To view Neurovia’s complete valuation and funding history, request access »

Neurovia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Neurovia’s complete cap table history, request access »

Neurovia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a
Biotechnology
San Francisco, CA

Daejeon, South Korea
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurovia Competitors (15)

One of Neurovia’s 15 competitors is Biorchestra, a Venture Capital-Backed company based in Daejeon, South Korea.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biorchestra Venture Capital-Backed Daejeon, South Korea
Neurocrine Biosciences Formerly VC-backed San Diego, CA
Lineage Cell Therapeutics Corporation Carlsbad, CA
Regulus Therapeutics Pending Transaction (M&A) San Diego, CA
Voyager Therapeutics Corporation Lexington, MA
You’re viewing 5 of 15 competitors. Get the full list »

Neurovia FAQs

  • When was Neurovia founded?

    Neurovia was founded in 2013.

  • Where is Neurovia headquartered?

    Neurovia is headquartered in San Francisco, CA.

  • What industry is Neurovia in?

    Neurovia’s primary industry is Biotechnology.

  • Is Neurovia a private or public company?

    Neurovia is a Private company.

  • What is Neurovia’s current revenue?

    The current revenue for Neurovia is .

  • How much funding has Neurovia raised over time?

    Neurovia has raised $13.9M.

  • Who are Neurovia’s competitors?

    Biorchestra, Neurocrine Biosciences, Lineage Cell Therapeutics, Regulus Therapeutics, and Voyager Therapeutics are some of the 15 competitors of Neurovia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »